Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM). We report results of an early access protocol (EAP) of daratumumab monotherapy for RRMM in a cohort of Brazilian patients. Methods:...

Full description

Saved in:
Bibliographic Details
Main Authors: Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Angelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Trufelli, Mariana Fernandez, Luciana Barreto Herriot
Format: article
Language:EN
Published: Elsevier 2021
Subjects:
Daratumumab
Monoclonal antibody
Multiple myeloma
Early access protocol
Brazil
Diseases of the blood and blood-forming organs
RC633-647.5
Online Access:https://doaj.org/article/1f1e7ed4750b4a32812d19e02ced92d7
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items